Global Prils Market is estimated to be US$ 3496.8 million by 2030 with a CAGR of 4.4% during the forecast period - by PMI
30. April 2021 10:35 ET
|
PMI
Covina, CA, April 30, 2021 (GLOBE NEWSWIRE) -- The Global Prils Market accounted for US$ 2388.6 million in 2020 and is estimated to be US$ 3496.8 million by 2030 and is anticipated to register a...
ROSEN, A LEADING LAW FIRM, Reminds Mylan N.V. Investors of Important Tuesday Deadline in Securities Class Action – MYL
23. August 2020 12:46 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 23, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7,...
Jubilant Receives Favorable Rulings from the U.S. Patent Office Invalidating Bracco Rubidium-Infusion-System Patents
17. Februar 2020 08:00 ET
|
Jubilant Pharma
YARDLEY, Pa., Feb. 17, 2020 (GLOBE NEWSWIRE) -- On February 7, 2020, Jubilant DraxImage Inc., and certain of its affiliates (“Jubilant”) were informed by the U.S. Patent Office that it agreed with...
Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime®
27. Januar 2020 16:05 ET
|
Jubilant Pharma
YARDLEY, Pa., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Jubilant Radiopharma, the Radiopharmaceutical Division of Jubilant Pharma Ltd, announced today that the company received approval from Health Canada...
Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine
07. September 2017 07:50 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract presenting data from the Phase 3 SECURE...
Agile Therapeutics Reports Second Quarter 2017 Financial Results
28. Juli 2017 07:30 ET
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
27. Juli 2017 16:11 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...
Agile Therapeutics Reports First Quarter 2017 Financial Results
08. Mai 2017 16:11 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company today reported financial results for the three months ended March 31, 2017, and...
Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017
06. Mai 2017 14:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 06, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced the presentation of additional results of its Phase 3 SECURE...
Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
11. April 2017 07:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 11, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced it has received the final meeting minutes from its recent...